Ascendis Pharma (ASND) said Monday it submitted a supplemental biologics license application to the US Food and Drug Administration for pediatric growth hormone deficiency drug TransCon hGH, now targeting adults with growth hormone deficiency.
The submission is based on data from a phase 3 trial, the company said. The treatment was generally safe and well tolerated and no discontinuations were reported related to the study drug, it added.
Price: 144.50, Change: -0.12, Percent Change: -0.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.